Destiny Pharma PLC
LSE:DEST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its Industry Average (0), the stock would be worth GBX0 (100% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | GBX3 |
0%
|
| Industry Average | 0 | GBX0 |
-100%
|
| Country Average | 0 | GBX0 |
-100%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Destiny Pharma PLC
LSE:DEST
|
2.9m GBP | 0 | -0.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 0 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 9.6 | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.8B USD | 7.2 | 23 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 7.5 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 769.8 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 9.6 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 4.2 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 11.9 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 26 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 6.4 | 29.5 |
Market Distribution
Other Multiples
Destiny Pharma PLC
Glance View
Destiny Pharma Plc engages in the discovery, development and commercialization of new antimicrobial products. The company is headquartered in Brighton, Sussex. The company went IPO on 2017-09-04. The firm is engaged in the discovery, development, and commercialization of novel medicines with a focus on infection prevention. The company is focused on developing novel antimicrobial drug from its exeporfinium chloride platform and also from two biotherapeutic products. Its pipeline includes XF-73 nasal gel, NTCD-M3, and XF-73 dermal. XF-73 nasal gel is developed for the prevention of post-surgical staphylococcal infections. NTCD-M3, which is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins. NTCD-M3 is used for the prevention of C. difficile infection (CDI) recurrence. XF-73 derma is developed for the prevention and treatment of serious infections associated with wounds and ulcers such as diabetic foot ulcers (DFUs). The firm is co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections.
